Emily Mullin

Emily Mullin
Emily Mullin

Emily Mullin, Associate Editor

Before joining the Fierce life sciences team as an associate editor, Emily Mullin was a reporter at the Baltimore Business Journal, where she covered the healthcare and biotechnology industries, and a staff writer for Dorland Health, a healthcare trade publishing company based in Rockville, MD. She has served as a contributing writer to The Maryland Daily Record, where she’s covered topics ranging from neuroscience to hospital consolidation. Her business and healthcare stories have also appeared in Nephrology Times, Columbus Business First and the Cincinnati Business Courier. She is based in Washington, DC, and is a graduate of the E.W. Scripps School of Journalism at Ohio University. You can contact her at [email protected] and follow her on Twitter at @EmilyMFierce.

Stories by Emily Mullin

Inhaled Ebola vaccine may provide higher protection rate

A breathable, respiratory vaccine to guard against Ebola is the latest contender to join the race toward a treatment or vaccine to stop the spread of the deadly virus. Developed by researchers at the University of Texas at Austin, the vaccine has shown that a single dose of the vaccine showed long-term protection in monkeys.

Glaxo hep C vaccine delivers promising early results

Next-generation hepatitis C drugs may be breaking revenue records now, but eventually a vaccine to prevent the disease could cut into the cash cows' market share. That candidate might come from GlaxoSmithKline, whose hepatitis C vaccine just passed an early test, generating strong and broad immune responses not seen before against the transmissible liver disease.

Ebola vaccine trials beginning in Mali

Professor Myron M. Levine, MD, Director of the Center for Vaccine Development (CVD) at the University of Maryland School of Medicine (UM SOM), and UM SOM Dean E. Albert Reece MD, PhD, MBA, announced...